<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818125</url>
  </required_header>
  <id_info>
    <org_study_id>21 SEIN 01</org_study_id>
    <nct_id>NCT04818125</nct_id>
  </id_info>
  <brief_title>Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer.</brief_title>
  <acronym>CARMMYC</acronym>
  <official_title>Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot, prospective, monocentric study aimed at evaluating the rate of patients with&#xD;
      circulating cancer cell/macrophage hybrid cells in the peripheral blood.&#xD;
&#xD;
      The study will be conducted on a population of patients with breast cancer (regardless of&#xD;
      stage of the disease and the immunohistochemical subtype).&#xD;
&#xD;
      For each included patient, blood samples will be taken and tumor specimens will be collected&#xD;
      for the study.&#xD;
&#xD;
      At the end of the blood collection, the patient will have completed his participation in the&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with cancer cell / macrophage hybrid cells in peripheral blood defined as the ratio of the number of patients with hybrid cells to the total number of patients.</measure>
    <time_frame>20 months after the study start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of circulating hybrid cells in peripheral blood by automatic measurement (Cell Counter Corning) and expressed in number of cells / millilitre of blood.</measure>
    <time_frame>20 months after the study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) defined as the time from the date of inclusion to the date of progression or death from any cause.</measure>
    <time_frame>20 months after the study start</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with breast cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients with breast cancer (stage I, II III or IV)</intervention_name>
    <description>Blood samples will be collected at different times:&#xD;
at Baseline for all patients with breast cancer: before initiation of treatment (i.e. before initiation of planned treatment for stage I to III patients and before any new line of treatment for stage IV patients);&#xD;
at the time of disease progression (or at 12 months in absence of progression) for patients with metastatic breast cancer (stage IV)&#xD;
For each patient a tumor sample from the initial diagnosis of the disease (i.e. primary tumor +/- biopsy of a metastasis) will be collected (archived tumor block) for the study.</description>
    <arm_group_label>Patients with breast cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with breast cancer of any stage (stage I, II, III or IV) and any&#xD;
             immunohistochemical subtype (triple-negative, HR+/HER2-negative or HER2-positive).&#xD;
&#xD;
          2. Patient not yet initiated on specific treatment for the stage of breast cancer at&#xD;
             inclusion.&#xD;
&#xD;
          3. Available tumor sample (archived tumor block) : initial tumor or metastasis depending&#xD;
             on the stage of the disease and availability.&#xD;
&#xD;
          4. Age â‰¥ 18 years old.&#xD;
&#xD;
          5. Patient affiliated to a Social Health Insurance in France.&#xD;
&#xD;
          6. Patient having signed informed consent prior to inclusion in the study and prior to&#xD;
             any specific study procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Associated pathology(ies) that may prevent the proper conduct of the procedure under&#xD;
             consideration.&#xD;
&#xD;
          2. Pregnant or breastfeeding woman.&#xD;
&#xD;
          3. Any psychological, family, geographical or sociological condition that prevents&#xD;
             compliance with the medical follow-up and/or procedures of the study protocol.&#xD;
&#xD;
          4. Patient who has forfeited his/her freedom by administrative or legal award or who is&#xD;
             under legal protection (curatorship and guardianship protection of justice).&#xD;
&#xD;
          5. Patient who has presented another solid tumor (except breast or cervix carcinoma in&#xD;
             situ) within 5 years.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Cancer cell/macrophage hybrid cells</keyword>
  <keyword>Hybrid cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

